Eli Lilly's weight-loss pill wins EU drug regulator's backing
LLY•The European Medicines Agency recommended approval of Eli Lilly's Foundayo for weight management and type 2 diabetes in adults. The European Commission will review the recommendation before making a final decision on launching the drug in the region.
1. EU recommendation
The European Medicines Agency's committee recommended marketing authorisation for Foundayo, Eli Lilly's oral drug for weight management and treatment of type 2 diabetes in adults. The European Commission will review the recommendation before making a final decision.
2. Sales and launch outlook
Foundayo launched in the United States in April and the United Kingdom in August, generating $98 million in second-quarter sales. Bernstein analyst Courtney Breen expects an EU obesity launch around year-end; for diabetes, Breen said launch timing depends on member-state reimbursement.
3. Competition and access
Novo Nordisk's Wegovy pill generated 3.22 billion Danish crowns ($484.50 million) in second-quarter sales and won EU approval in July. Foundayo contains orforglipron and can be taken at any time of day without food or water restrictions, unlike Wegovy; uptake in the United States has been slower than Wegovy's.




